The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center

Yeda Research and Develpment & Co. Ltd

Tel Aviv University

The Weizmann Institute of Science

The Medical Research Fund at the Tel-aviv Sourasky Medical Center

Medical Research and Infrastructure Fund of Tel-aviv Sourasky Medical Center

The Medical Research and Infrastructure Fund of the Tel-aviv Sourasky Medical Center

Naftali Stern

Gary Weisinger

Rona Limor

Anthony Futerman

Ari Zimran

Etty Osher

Dalia Somjen

Veronica Frydman

Ruth Navon

Tikva Kulik

Batya Gayer

Fortune Kohen

The present invention relates in general to the field of enzyme replacement therapy, and specifically to chimeric proteins including protein hormone-therapeutic protein conjugates and fusion proteins, wherein the protein hormone is selected from a protein hormone which is able to cross the blood brain barrier, for the treatment of lysosomal storage diseases, compositions of the same and to methods of use thereof.

Enzyme replacement therapy for treating lysosomal storage diseases

The present invention is directed to constructs, compositions and methods for modulating platelet-type 12 lipoxygenase (12-LO) in adipose tissue in vivo. Specifically, the invention provides constructs encoding expression-inhibiting oligonucleic acids, e.g. antisense and RNA interfering (RNAi) molecules, targeted to a platelet-type 12-LO gene or a transcript thereof, which are capable of reducing or silencing platelet-type 12-LO expression specifically in adipocytes and pre-adipocytes. Vectors comprising these constructs (including, but not limited to, viral vectors), compositions comprising them and methods of using same for the treatment and amelioration of conditions associated with excess fat cell mass and obesity are also provided.

Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression

The present invention is directed to constructs, compositions and methods for modulating platelet-type 12 lipoxygenase (12-LO) in adipose tissue in vivo. Specifically, the invention provides constructs encoding expression-inhibiting oligonucleic acids, e.g., antisense and RNA interfering (RNAi) molecules, targeted to a platelet-type 12-LO gene or a transcript thereof, which are capable of reducing or silencing platelet-type 12-LO expression specifically in adipocytes and pre-adipocytes. Vectors of these constructs (including, but not limited to, viral vectors), compositions of them and methods of using same for the treatment and amelioration of conditions associated with excess fat cell mass and obesity are also provided.

Isoflavone derivatives are provided comprising a carboxyalkylene moiety linked via its alkylene chain to the aromatic ring and via its carboxy group to an aminoalkyleneamino residue, which, in turn, is covalently linked to a functional group B. The isoflavone derivatives are preferably derived from biochanin A, genistein, and daidzein, and the functional group B is preferably an amino protecting group. These isoflavone derivatives are useful for treating or preventing diseases or disorders associated with estrogen receptor functioning.

Isoflavone derivatives and uses thereof

Growing community of inventors

Nir Zvi, Israel

Naftali Stern